Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

News SummaryMost relevantAll newsSector newsTweets 

Novo Nordisk B : In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/13/2012 | 10:15am CET
News In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

As part of an official Danish state visit to Kenya, Novo Nordisk on 12 April officially launched a programme to make insulin and diabetes care more accessible to poor populations.

In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients' homes.

The project has reduced price mark-ups in the supply chain to the extent that the insulin can be obtained at 20 cents daily, which is equivalent to a third of the previous price on the private market.

The Kenyan project is the first of three pilots to be launched by Novo Nordisk this year. A second one is about to be launched in India, and a third pilot will be launched in Nigeria later in 2012.

The pilot projects will create valuable learnings on how access to insulin and proper diabetes care can be improved for people with diabetes with very low incomes.

Worldwide, there is a population of 46 million people with diabetes who earn between 4 and 10 dollars per day. In 2030, this group is expected to grow to more than 73 million people.

Diabetes in Africa

According to the International Diabetes Federation, the growth of diabetes in Africa is currently the highest in the world. Close to 15 million people in sub-Saharan Africa currently have diabetes, and this number is expected to rise to around 28 million in 2030. It is estimated that 78% of people with diabetes today are undiagnosed.

In Kenya, the International Diabetes Federation estimates that there are currently around one million people with diabetes in Kenya with urban prevalence up to 10%.

Video from Kenya will be available here Monday.

Contacts details:

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVO NORDISK A/S
03/23 NOVO NORDISK A/S : New Proinsulin Study Findings Reported from Novo Nordisk [Tot..
03/23 NOVO NORDISK A/S : Resolutions from the Annual General Meeting of Novo Nordisk A..
03/20 NOVO NORDISK A/S : - Share repurchase programme
03/17 Special Purpose Needles Market 2017 - Cook Medical, MEDTRONIC, Smith's Medica..
03/17 CVS : Driving Affordable Solutions: Reduced Rx Prescription Savings Program
03/16 NOVO NORDISK A/S : Named on the FORTUNE 100 Best Companies to Work For® List for..
03/16 MARCH 13 DEADLINE ALERT : Law Offices of Howard G. Smith Reminds Novo Nordisk A/..
03/14 NOVO NORDISK A/S : New economic data finds Novo Nordisk's insulin degludec most ..
03/13 NOVO NORDISK A/S : - Share repurchase programme
03/11 Goldberg Law PC Announces Securities Class Action Lawsuit against Novo Nordis..
More news
Sector news : Pharmaceuticals - NEC
03:14a YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
03/23 TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/22 Novo Nordisk goes ex-dividend tomorrow
03/20 Valeritas Sets Terms For $60 Million Diabetes Treatment Device IPO
03/20 Corporate Venture Capital - Savior Of Medtech?
03/20 Novo Nordisk - Another Apple 2013 Story? New Highs Ahead?
03/20 SANOFI : What Are The Outlooks?
Financials ( DKK)
Sales 2017 116 343 M
EBIT 2017 50 059 M
Net income 2017 38 083 M
Finance 2017 14 512 M
Yield 2017 3,25%
P/E ratio 2017 15,19
P/E ratio 2018 13,65
EV / Sales 2017 3,91x
EV / Sales 2018 3,74x
Capitalization 469 934 M
More Financials
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 32
Average target price 269  DKK
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-8.32%68 237
JOHNSON & JOHNSON9.28%342 277
ROCHE HOLDING LTD.7.52%217 164
PFIZER INC.5.57%205 273
NOVARTIS AG-0.94%194 072
MERCK & CO., INC.7.49%174 344
More Results